CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2018--
Synlogic, Inc. (Nasdaq:
SYBX), announced today that the Company will release its third
quarter 2018 financial results after the market closes on Tuesday,
November 13, 2018. The press release will be followed by a conference
call at 5:00 p.m. ET, which will be open to the public via telephone and
webcast. During the conference call, the Company will review its
financial results and provide a corporate update.
The conference call dial-in numbers are (844) 815-2882 for domestic
callers and (213) 660-0926 for international callers. The conference ID
number for the call is 2674209. Participants may access the live webcast
via a link on the Synlogic website in the Events
Calendar of the Investors and Media section.
Synlogic is pioneering the development of a
novel class of living medicines, Synthetic Biotic medicines, based on
its proprietary drug development platform. Synlogic leverages the tools
and principles of synthetic biology to genetically engineer beneficial
microbes to perform or deliver critical functions missing or damaged due
to disease. Synthetic Biotic medicines are designed to act locally and
have a systemic effect to address disease in patients. Synlogic’s two
lead programs, SYNB1020 and SYNB1618, are orally administered and target
hyperammonemia as a result of liver damage or genetic disease, and
phenylketonuria, respectively. Synlogic is also developing SYNB1891 as
an intratumorally administered Synthetic Biotic medicine for the
treatment of cancer. In addition, the company is leveraging the broad
potential of its platform to create additional Synthetic Biotic
medicines for the treatment of liver disease, as well as inflammatory
and immune disorders, including Synlogic’s collaboration with AbbVie to
develop Synthetic Biotic-based treatments for inflammatory bowel disease
(IBD). For more information, please visit www.synlogictx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181107005912/en/
Source: Synlogic, Inc.
Elizabeth Wolffe, Ph.D., 617-207-5509